Xilonix: Additional Phase III data

XBiotech reported additional data from a double-blind, European Phase III trial in 309 patients with symptomatic, refractory, metastatic colorectal cancer evaluating IV Xilonix every 2 weeks plus

Read the full 272 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE